Toxicological and pharmacodynamic evaluation of Nixodine-S [(S)-6-Methylnicotine] relative to (S)-nicotine Authors: Marissa L Smith, Sandra Costigan, J Preston Campbell, Rick Avila, Roxana E Weil, Willie J McKinney Published: 2026 ABSTRACT Abstract6-Methylnicotine (6-MN) products are increasingly appearing on the US and global markets and are currently unregulated in the US. Nixodine-S is a flavorless concentrate containing (S)-6-MN for use as a 1:1 nicotine alternative in the manufacture of vape or oral products. Based on intravenous acute toxicity study results, it was formulated to be less acutely toxic than nicotine. Under volume-equivalent dosing conditions, the Nixodine-S formulation did not induce cytotoxicity in the neutral red uptake assay with BALB/c 3T3 cells, while nicotine was cytotoxic. Both Nixodine-S and nicotine were negative in micronucleus and Ames assays. In nAChR activation testing, Nixodine-S, as well as its salt, elicited similar activation of two nAChR subtypes that are implicated in nicotine reward pathways. Nixodine-S and its salt produced a response consistent with weak partial agonism (low intrinsic efficacy relative to acetylcholine) similar to nicotine but with much lower potency than nicotine, at the most nicotine-sensitive of the three receptors tested and a primary driver of phasic dopamine release in mesolimbic reward circuits. Collectively, these data support an exploratory receptor-referenced therapeutic index (rTI) for Nixodine-S that is comparable to that of nicotine at volume-equivalent doses, and a differential nAChR subtype profile.Keywords: 6-methylnicotine, Nicotine, Nicotine analog, Acetylcholine receptor, Cytotoxicity, Genotoxicity, Mutagenicity Introduction Nicotine analogs are increasingly being used as alternatives to nicotine in products such as e-cigarettes and oral pouches. Commercial drivers have led to the development of several nicotine analog-based bulk materials with varying strengths and chemical characterization over the past several decades, and current evidence suggest these nicotine analog-based bulk materials may differ from nicotine in their pharmacological and toxicological profiles. (S)−6-Methylnicotine [(S)−6-MN] shares the core pharmacophore of (S)-nicotine, with a methyl substituent at the 6-position of the pyridine ring. Published binding studies demonstrate 3–10-fold greater nAChR affinity for (S)−6-MN relative to nicotine [1], [2], raising the central question of whether greater receptor potency translates to proportionally greater acute hazard or abuse liability at volumetrically equivalent consumer-relevant exposures. This work contributes to that question by comparing nicotine and Nixodine-S. Proprietary intravenous acute toxicity rat data on nicotine and (S)−6-MN has informed the formulation of Nixodine-S to achieve a concentrate intended for use as a volume-to-volume replacement for nicotine, with a (S)−6-MN concentration that results in no more acute central nervous system toxicity than nicotine. In the studies reported here, Nixodine-S is dosed at equivalent volumes to nicotine. This means it is compared in in vitro testing, at levels where Nixodine-S would result in the same, or less, in vivo acute central nervous system toxicity as nicotine. In this way, a comparison is made between those aspects of the pharmacological and toxicological profiles of nicotine and (S)−6-MN. To integrate toxicological hazard and pharmacological potency into a single interpretable metric, we apply the receptor-referenced therapeutic index (rTI), defined as the ratio of the acute median lethal dose (LD₅₀) to the half-maximal effective concentration at the primary reward-pathway receptor subtypes = LD50 (mg/kg) / EC50 (α4β2*) [µg/mL], where EC50 is expressed as a mass/volume concentration derived from v/v dose × compound MW (nicotine MW = 162.23 g/mol). A higher rTI indicates a wider safety margin between meaningful receptor engagement and acute toxicity, analogous to the classical therapeutic index used in drug development. Nixodine-S is a formulated concentrate containing (S)−6-MN and should not be considered equivalent to neat (S)−6-MN or to other commercial 6-MN-containing materials. Besides (S)−6-MN and Nixodine-S, various other 6-MN-based bulk products exist, such as “Imotine”, “Ceretine”, and “Metatine”. These differ in chemical characterization, including different 6-MN concentrations, chirality, solvents, and combinations with other ingredients. Conclusions from this work on one of these products, Nixodine-S, are thus not equally applicable to all 6-MN-containing products and additional work is needed to characterize the risks of other 6-MN-containing products. Background Similar to previously conducted acute intravenous in vivo studies, our unpublished study identified a lower ED₅₀ for clonic convulsions for (S)−6-MN than nicotine, and a lower LD₅₀ for (S)−6-MN relative to literature-based LD₅₀ values for nicotine [3], [4]. These data informed the dilution of (S)−6-MN in the development of Nixodine-S to decrease the acute toxicity potential of Nixodine-S to below that of nicotine on a volumetric equivalence basis. As previous literature suggests (S)−6-MN may have greater nAChR binding affinity [1], [5], the Phase 3 additional studies within this paper were conducted to investigate whether the increased binding affinity translates to increased efficacy and potency, and potential cell viability, genotoxicity, and mutagenicity hazards in vitro (Fig. 1). (S)−6-MN and Nixodine-S in vivo and in vitro evaluation program design. Methods Nicotinic acetylcholine receptor activation assay Agonistic nAChR activation was assessed on neat (S)-nicotine, Nixodine-S, and Nixodine-S Salt samples on cloned human channels in mammalian cells at Charles River Discovery (Cleveland, Ohio). HEK293 cells expressing α6/3β2β3 (human CHRNA6, CHRNA3, CHRNB2, and CHRNB3 genes) were maintained in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F−12 (DMEM/F−12) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, and selection antibodies. CHO cells expressing α3/β4 (human CHRNA3 and CHRNB4) or α4/β2 (human CHRNA4 and CHRNB2 genes) were maintained in Ham’s F−12 supplemented with 10% FBS, 100 U/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, and selection antibodies. Cells were plated at 15,000–30,000 cells per well and incubated until reaching a near confluent monolayer. The FLIPR Tetra® assay was conducted according to the FLIPR membrane potential red dye kit manufacturer’s instructions (Molecular Devices). Four replicates of each test article concentration, vehicle control, and acetylcholine positive control concentration were added by FLIPR to respective wells and agonist activity recorded for approximately five minutes. Data were acquired via FLIPR MDS-AT Control software and fit to a four-parameter Hill equation using GraphPad Prism (v10; GraphPad Software, San Diego, CA). Additional statistics were performed in Python and confirmed in Microsoft Excel v2405 + /Build 16.0). All rTI and EC50 comparisons are based on mass/volume (µg/mL) units consistent with v/v dosing. For the α6/3β2β3 subtype, data were fit to both a three-parameter inhibitory sigmoidal model and the Black–Leff operational partial agonist model; model selection was based on F-test comparison (α = 0.05) and goodness-of-fit (R², AIC). If the partial agonist model provided a statistically equivalent or superior fit, the test article was classified as a weak partial agonist with low intrinsic efficacy (τ < 1 relative to acetylcholine) rather than as a functional desensitizer. Potency ratios were calculated as EC₅₀(nicotine)/EC₅₀(test compound) ± 95% CI in µg/mL from nonlinear regression. in vitro toxicology assays Cytotoxic, genotoxic, and mutagenic potential were assessed on neat (S)-nicotine and Nixodine-S samples at McKinney Specialty Labs (Richmond, Virginia). Nicotine and 6-MN were quantified by gas chromatography (GC) with flame ionization detection (FID) at assay initiation and at eight weeks after dose preparation to confirm sample stability throughout testing and the nicotine concentration was used to calculate the volumetric concentrations tested in the NRU [6], ivMN [7], and Ames [8] assays. These studies were selected as they are a common part of the safety profile expected in Premarket Tobacco Product Applications (PMTA) for Electronic Nicotine Delivery Systems (ENDS) and pouches, which are relevant products for Nixodine-S use. Neutral red uptake (OECD TG 129) The NRU assay was conducted to evaluate cytotoxicity. BALB/c 3T3 cells were obtained from ATCC (Manassas, Virginia), cryopreserved, and used within 16 passages after removal from liquid nitrogen. 3T3 cells were cultured in DMEM supplemented with 10% bovine calf serum (BCS), 1000 units/mL penicillin, and 10 mg/mL streptomycin. BALB/c 3T3 cells were seeded in triplicate 96-well microplates at a density of approximately 3000 cells/well in 100 μL of growth medium supplemented with 10% heat-inactivated BCS in all test sample and vehicle control wells. 100 μL of growth media without cells was added to wells on the perimeter of the microplate as blanks. Plates were incubated at 37°C and 5% CO₂ for 24 h. Following initial incubation, growth media was removed from each well and 100 μL of growth media containing each test sample, sodium lauryl sulfate (SLS) as a positive control, or dimethyl sulfoxide (DMSO) as a vehicle control, was added to each well. Plates were incubated at 37°C and 5% CO₂ for 48 h. Neat (S)-nicotine was tested at concentrations up to the solvent-limited maximum dose. Nixodine-S was diluted with DMSO to produce volume-equivalent concentrations matching those tested for nicotine. Following test article exposure, plates were visually inspected for cell seeding errors and precipitation. Treatment media was removed from each well and cells rinsed with 250 μL pre-warmed Dulbecco’s Phosphate Buffered Saline (D-PBS). 250 μL of neutral red medium was added to each well and the plates incubated for 3 h. Following incubation, the neutral red medium was removed and the cells rinsed with 250 μL D-PBS. 100 μL neutral red desorb solution was added to each well and the plates shaken on a microtiter plate shaker for 20–45 min, protected from light. Within 60 min of addition of desorb solution, plates were read at 540 ± 10 nm on a plate reader. GraphPad Prism was used to determine IC50 values using a four-parameter logistical model and the Hill function, with top set to 100% and bottom set to 0% viability. Osmolality was measured using a Multi-Osmette 2430 in triplicate and pH was measured using a standard pH meter on the three highest test sample concentrations, growth medium, and growth media with DMSO. Micronucleus (ivMN; OECD TG 487) The micronucleus assay was conducted to evaluate genotoxicity. TK6 Human lymphoblast cells were selected for the ivMN assay. Cells were obtained from ATCC, cryopreserved, and used within 15 passages after removal from liquid nitrogen. TK6 cells were cultured in RPMI−1640 growth medium supplemented with L-glutamine, heat-inactivated FBS, 1000 units/mL penicillin, and 10 mg/mL streptomycin. TK6 cells were dispensed in flasks in duplicate and incubated at 37°C and 5% CO₂ for 24 h, after which the growth medium was removed and growth medium containing test samples, EtOH vehicle control, or a positive control was added to the cells in each flask. Cytotoxicity-based concentrations of 0.1, 0.2, 0.4, 0.8, 1.5, 3.0, 6.1, and 12.1 μg/mL (S)-nicotine and v/v equivalent doses of Nixodine-S were tested in the presence and absence of rat liver S9 metabolic activation. The metabolic activation mixture contained phenobarbital−5,6 benzoflavone-induced S9 rat liver fraction, DL-isocitric acid trisodium salt solution, and nicotine adenine dinucleotide phosphate (NADP) solution. Cells were transferred to 50 mL centrifuge tubes and exposed to the test samples, positive controls, and negative control under 3 treatment schedules. The positive control for Schedule i was methyl methanesulfate, for Schedule ii was cyclophosphamide, and for Schedule iii was vinblastine. For short-term treatments, cells were incubated with treatment media in the absence (Schedule i) or presence (Schedule ii) of metabolic activation for 4 h at 37°C and 5% CO₂. Following the treatment period, tubes were centrifuged, cells washed with D-PBS, resuspended in growth media, and the cell suspension transferred to tissue culture flasks, and incubated at 37°C and 5% CO₂. For Schedule iii, cells were transferred to 50 mL centrifuge tubes and incubated with treatment media, in the absence of metabolic activation, for 27 h. Following the treatment period, treatment media was removed, and cells were washed with D-PBS. Following the Schedule i and ii recovery period and Schedule iii treatment period, cells were transferred to conical tubes and an aliquot mixed with trypan blue for cell quantification. Based on cell counts, adjusted volumes of cell suspension were transferred to 15 mL centrifuge tubes and processed for flow cytometry. Tubes were centrifuged, the supernatant removed, the cell pellet resuspended, and the tubes placed on ice for 20 min before following the Litron Laboratories MicroFlow cell staining protocol. For each test sample concentration and positive control, cell proliferation and cytotoxicity were determined based on relative population doubling. GraphPad Prism was used to conduct ordinary one-way Analysis of Variance (ANOVA) test followed by Dunnett’s multiple comparison test to determine statistically significant differences between the vehicle control and the test substance %MNC. A Cochran-Armitage test for trend was conducted to evaluate dose dependency of the test substance. If the average micronuclei responses for all test concentrations tested fell below the laboratory’s upper historical no statistical analysis was conducted and the test results considered negative. Bacterial reverse mutation assay (Ames; OECD TG 471) The Ames assay was conducted to evaluate mutagenicity, a predictor of potential carcinogenicity. Salmonella Typhimurium TA98, TA100, TA102, TA1535, and TA1537 strains were inoculated from frozen stock in late log phase by shaking 10–14 h at approximately 120 rpm. Culture turbidity was monitored by spectrophotometry, and the density adjusted to 10⁹ cells/mL after incubation. Strain genotyping was confirmed by exhibiting growth in the presence of histidine-biotin and absence of growth in the presence of biotin alone, exhibiting sensitivity to crystal violet to confirm presence of the rfa mutation, growth of TA102 and absence of growth in TA98, TA100, TA1535, and TA1537 when exposed to ultraviolet light to confirm the uvrB mutation, growth in TA98, TA100, and TA102 and no growth in TA1535 and 1537 in the presence of ampicillin to confirm the pKM101 plasmid R-factor mutation, and resistance to tetracycline in TA102. The Ames assay was conducted in triplicate plates in the presence and absence of rat liver S9 metabolic activation. The S9 mixture contained deionized water, phosphate buffer, NADP solution, glucose−6-phosphate solution, magnesium chloride-potassium chloride solution, and phenobarbital−5,6 benzoflavone-induced rat liver S9. Reaction mixtures were prepared by adding phosphate buffer or S9 mix, EtOH, test sample or positive control, and overnight bacterial culture. The reaction mixture was vortexed and shaken while incubated at 37°C for 20 min. Top agar was added to each tube and the mixture poured onto plated minimal glucose bottom agar. Plates were allowed to solidify and then were inverted and incubated 48–72 h at 37°C. Colonies were counted with an automated colony counter. GraphPad Prism was used to conduct an ordinary one-way Analysis of Variance (ANOVA) test followed by Dunnett’s multiple comparison test to determine statistically significant differences between each tested non-zero dose and the concurrent vehicle control. If the ANOVA test was not significant or if the fold increase of the non-zero dose did not meet the minimum fold increase requirement for the tester strain, Dunnett’s multiple comparison test results were considered negative. Results Nicotinic acetylcholine receptor activation Overall, Nixodine-S exhibited nicotine-like agonist activity across α3β4, α4β2, and α6/3β2β3 nAChRs, demonstrating comparable or slightly greater potency at α3β4 and α4β2, but reduced potency and efficacy at α6/3β2β3 relative to nicotine. Table 1Receptor Subtype Activation Profiles.Receptor subtypeNicotine EC₅₀ (µg/mL)Nixodine-S EC₅₀ (µg/mL nic-eq)Relative potencyNicotine max activation (% ACh)Nixodine-S max activation (% ACh)ACh EC₅₀ (µg/mL)α3β40.1980.141Potency difference less than 2-fold951030.501α4β20.0890.047Potency difference less than 2-fold1051280.107α6/3β2β3< 0.00160.03Nicotine > 19-fold more potent51380.09 Receptor Subtype Activation Profiles. Nicotine demonstrated partial activation with the EC50 below the lowest concentration tested (<0.0016 µg/mL), consistent with orders of magnitude higher potency than ACh at this subtype. Nixodine-S functioned as a much weaker, and even more partial agonist, producing a concentration-dependent increase in FLIPR signal that reached a plateau of approximately 38% of ACh control across the tested range (0.0016–0.487 µg/mL). Using a vehicle-anchored 4-parameter logistic model (Bottom = 0%, Top = compound Emax), the EC50 for Nixodine-S was estimated at 0.03 µg/mL (R² = 0.96). While nicotine was > 19-fold more potent than Nixodine-S at α6, the true ratio may be much larger as this is not possible to derive from the available data. Note, the Prism-derived EC50 of 0.618 µg/mL assumes Top = 100% (ACh reference), a constraint that is inappropriate for a partial agonist whose maximum response (38% ACh) falls below the 50% midpoint of that reference scale; that value is therefore not relevant. For all 3 receptor types, the Nixodine-S Salt results were comparable to those for Nixodine-S (Fig. 2). nAChR Functional Activity of (S)-Nicotine and Nixodine-S at Three Receptor Subtypes (n = 4 per concentration point). Cytotoxicity The IC₅₀ of the SLS positive control fell within historical laboratory controls, vehicle control mean uncorrected absorbance differences between the right and left sides of the plates were < 15%, and no substantial changes in pH or osmolarity were observed. At concentrations up to 2000 µg/mL nicotine and the volumetric equivalent of Nixodine-S in BALB/c 3T3 cells, nicotine was cytotoxic (IC₅₀: 961.8 µg/mL) and Nixodine-S was not cytotoxic under the conditions of the assay (Fig. 3). Neutral Red Uptake Assay Cell Viability. Dotted line represents 70% viability limit per ISO 10993–5[9]. Genotoxicity The samples were evaluated in the micronucleus assay in TK6 cells in the presence and absence of S9 metabolic activation (Fig. 4). The positive and negative controls demonstrated assay validity. Nicotine and Nixodine-S were non-genotoxic under all treatment schedules under the conditions of the assay. Micronucleus Assay. Dotted line represents concurrent vehicle control. Mutagenicity The samples were evaluated in the Ames assay using S. typhimurium strains TA98, TA100, TA102, TA1535, and TA1537 in the presence and absence of S9 metabolic activation. The negative and positive controls elicited expected revertants colony counts, and mean revertants per plate for the definitive assay are listed in Table 2. Neither nicotine nor Nixodine-S were mutagenic under the conditions of the assay. Table 2Bacterial reverse mutation assay — mean revertants per dose level.StrainS9Mean Revertants per Dose Level - Nicotine0 µg/ plate70.4µg/plate141 µg/plate282 µg/plate563 µg/plate1130 µg/plate2250 µg/plate4510 µg/plateTA98-S92416231624262526+S94951454745465049TA100-S9121132127127126134149T+S9146141140134142145142135TA102-S9441425430437435427482487+S9573511504501496537511426TA1535-S91716162217201814+S91621171418161411TA1537-S91213151013121210+S91521181613121120StrainS9Mean Revertants per Dose Level - Nixodine-S (v/v nicotine equivalent doses)0 µg/plate70.4µg/plate141 µg/plate282 µg/plate563 µg/plate1130 µg/plate2250 µg/plate4510 µg/plateTA98-S92420241924222228+S95047474141524850TA100-S9114121111119131103120126+S9132152150150136148138143TA102-S9420442419406420397381383+S9501471469477489494484515TA1535-S92020131921221319+S91820171917221515TA1537-S99610811111111+S91317141410151619T = cytotoxic based on background lawn reduction Bacterial reverse mutation assay — mean revertants per dose level. T = cytotoxic based on background lawn reduction Discussion Only limited toxicology data exist on (S)−6-MN and 6-MN. A review of the literature did not produce original publications with respect to in vivo repeated dose studies (oral, dermal or inhalation) such as carcinogenicity, neuro- and immune-toxicity, local toxicity, sensitization, reproductive and developmental toxicity studies. However, acute toxicity and cytotoxicity studies suggest (S)−6-MN is more acutely toxic than nicotine. Tobacco industry internal documents indicate both (R,S)- and (S)−6-MN were approximately 4–5 times as acutely toxic as L-nicotine in a male mouse intravenous assay. Specifically, an LD₅₀ of 0.750 (C.I. 0.663–0.888) µmol/kg was reported for (R,S)−6-methylnicotine (referred to as compound CR−1589). Death was mediated via central nervous system toxicity, with a median effect dose for convulsions (ED₅₀) of 0.464 (C.I. 0.414–0.520) µmol/kg with 61.9% showing the response. For (S)−6-methylnicotine (referred to as CR−1542) the LD₅₀ and ED₅₀ were slightly higher at respectively 1.10 and 0.619 µmol/kg. These values were compared to the LD₅₀ and ED₅₀ for L-nicotine tested in the same type of assay and the ratios were respectively LD₅₀: 0.261 for (R,S)−6-MN versus nicotine, 0.383 for (S)−6-MN versus nicotine, ED₅₀: 0.237 and 0.215, respectively. This is comparable to the differences found in the unpublished, proprietary, intravenous acute toxicity testing performed in rats with (S)−6-MN and nicotine, that informed the formulation of Nixodine-S. Chirality is an important consideration for many compounds, including nicotine, as biological targets may distinguish between enantiomers. This may result in differences in pharmacokinetics, receptor activity, metabolism, and toxicity. (S)- and (R)- nicotine are well known to exhibit different receptor affinities and pharmacological activity, while also having different metabolic profiles. As the 6-MN within Nixodine-S and the nicotine were both S-enantiomers, the present study was not designed to evaluate chirality contributions to the observed toxicological and pharmacodynamic responses. From a regulatory perspective, the stereochemical purity of chiral active ingredients should be appropriately characterized and controlled. Comparative evaluation of R−6-MN would become more relevant if it were identified as a manufacturing impurity, degradation product, or metabolite of a future commercial product. In vitro, Nixodine-S was not cytotoxic in the NRU assay at more than twice the mass/volume equivalent (µg/mL) of nicotine's IC₅₀ (961.8 µg/mL), and both compounds were negative in ivMN and Ames assays. In other words, at comparable in vivo acute toxicity dosing volumes, Nixodine-S appears less cytotoxic than nicotine, while neither compound showed evidence of mutagenicity or clastogenic/aneugenic activity in standard in vitro batteries. In receptor pharmacology assays conducted at volume, and therewith comparable in vivo acute toxicity dosing, Nixodine-S exhibited similar, if somewhat greater potency and efficacy at both α4β2 and α3β4 than nicotine. These are the main receptors involved in nicotine reward driven responses important to both consumer satisfaction and abuse liability potential [10], [11], [12], [13]. The marked difference was at the α6/3β2β3 receptor: All three test articles are partial agonists at α6/3β2β3, with maximum activation of 35–51% of ACh control, well below full agonism. Nicotine's response is essentially flat across the entire tested concentration range (33.8–50.8% over a 3,000-fold range). This flat profile indicates that the EC50 falls below the lowest concentration tested (0.0016 µg/mL), such that all tested doses lie on the upper plateau of the concentration–response curve. This is distinct from a biphasic or bell-shaped profile, in which a descending limb at higher concentrations would reflect receptor desensitization or functional antagonism; no such descent is observed. Nixodine-S produced a concentration-dependent increase in net FLIPR signal consistent with weak partial agonism (low intrinsic efficacy) under the assay conditions employed. Functional desensitization cannot be excluded without time-sequences of the activation level, sequential additions of activating compounds or electrophysiological confirmation but is not the preferred interpretation based on operational model analysis. These various receptors, and interplays between them, are known to play a role in many different aspects of consumer satisfaction and reward, abuse liability and acute and peripheral toxicity. Although the differences were small and not statistically significant, an indication was observed for Nixodine-S effects on α4β2 and α3β4 being slightly stronger than nicotine, both with slightly lower EC50 (i.e. higher potency) and slightly higher maximum activation levels (i.e. efficacy). Thus, if brain exposure and receptor occupancy are comparable, Nixodine-S, if anything, might produce a slightly stronger α4β2- and α3β4-mediated dopaminergic drive than nicotine. At the α6/3β2β3 receptor, which has the lowest EC50 for nicotine (<0.0016 µg/mL) and is the principal driver of phasic dopamine amplification at nucleus accumbens terminals [14], Nixodine-S produced a concentration-dependent increase in net FLIPR signal reaching a plateau of approximately 38% of ACh control across the tested range (0.0016–4.87 µg/mL[nic-eq]), consistent with weak partial agonism. Fitting the Black–Leff operational partial agonist model suggests Nixodine-S may act as a weak partial agonist at this subtype, with intrinsic efficacy only slightly below that of nicotine but potency orders of magnitude less. Functional desensitization remains a possible mechanistic contributor but cannot be distinguished from weak partial agonism using FLIPR data alone; time-sequencing of the response, a second test article addition step or electrophysiological confirmation is required. This possible mechanistic distinction of whether functional desensitization is taking place for both test articles and in equal measures may be more consequential to the abuse liability profile than a simple potency comparison and warrants additional studies. A receptor-specific therapeutic index (rTI) was defined as the ratio of the acute in vivo LD₅₀ (mg/kg, [species, route]) to the in vitro α4β2* EC₅₀ (µg/mL) for each test article and then expressed relative to nicotine (rTI = TI_[test article] / TI_[nicotine]). Using this approach and assuming volume equivalence of Nixodine-S with nicotine, the rTI for Nixodine-S was approximately 4.35-fold higher than that of nicotine. Within the assumptions of this exploratory framework, the relationship between acute toxicity and α4β2 potency does not appear less favorable for Nixodine-S than for nicotine. The rTI should be interpreted as a comparative framework for integrating acute toxicity and receptor potency data, rather than a validated predictor of human abuse liability. Full rTI modeling incorporating human pharmacokinetic parameters is deferred to future work. The mesocorticolimbic system, often associated with nicotine reward, is also essential in regulating nicotine aversion. Particularly, the medial habenula–interpeduncular nucleus (MHb–IPN) pathway plays a critical role in regulating the avoidance of noxious stimuli and adaptive behaviors [15]. The enrichment and functioning of α3β4-containing receptors in the MHb–IPN pathway is said to be essential for nicotine avoidance behaviors. Nixodine-S’ slightly greater potency at α3β4 can therefore also suggest earlier activation of the MHb–IPN aversive circuitry than nicotine. Activation of these pathways is, amongst others, associated with increased aversive signaling, which could therefore contribute to aversion-related signaling pathways associated with reduced nicotine intake. Stronger aversive reactions to nicotine after initial exposure have been shown to be negatively correlated with the progression to regular smoking [16]. Both this (α3β4-mediated aversive signaling) and the weak partial agonism of Nixodine-S at α6/3β2β3 described above may represent two separate pharmacological mechanisms that, together, could reduce the reinforcing efficacy of Nixodine-S relative to nicotine: aversive dose-limitation via MHb–IPN circuitry, and attenuated mesolimbic dopamine amplification via reduced α6* efficacy. These receptor subtype differences generate testable hypotheses regarding altered reinforcement liability that require confirmation in behavioral pharmacology and human studies. In 3T3 cells, there was no sign of cytotoxicity for Nixodine-S in NRU at v/v concentrations where nicotine already produced full loss of cell viability. Receptor mediated signaling (agonism) at these nAChRs does therefore not directly translate to lysosomal/cell viability damage. This indicates that comparable, or somewhat higher receptor efficacy, is not related to toxicities dependent on cytotoxic effects. The present study has several acknowledged limitations, including reliance on receptor and cellular data. nAChR characterization is limited to single exposure, functional FLIPR assays and does not include radioligand competition binding, competitive antagonist studies (e.g., DHβE for α4β2*, mecamylamine for α3β4*, α-conotoxin MII analogues for α6*), patch-clamp electrophysiology, or in vivo behavioral pharmacology (e.g., self-administration, conditioned place preference). The study also did not evaluate R−6-MN or provide a comparison of the 6-MN enantiomers. The findings are specific to the tested formulations and should not be extrapolated to racemic or R−6-MN. The FLIPR signal profile at α6/3β2β3 is interpreted as evidence of weak partial agonism based on Black–Leff operational model analysis; however, functional desensitization cannot be excluded without time-sequencing, sequential exposures, electrophysiological confirmation (patch-clamp, single-channel recording) or competitive antagonist studies (e.g., α-conotoxin MII analogues for α6* selectivity). These studies constitute the experimental program of potential additional work. Translation from in vitro pharmacology to in vivo consumer effects remains speculative without human PK/PD data, behavioral pharmacology, and abuse liability studies. Furthermore, receptor activation was characterized under controlled in vitro assay conditions that do not fully replicate the complexity of the in vivo environment. Receptor expression, receptor stoichiometry, endogenous neurotransmitter tone, receptor desensitization, and pharmacokinetic factors may influence receptor interactions under physiological conditions. Future studies using animal models and integrated PK/PD approaches will be important to determine whether the receptor subtype differences observed here translate into differences in toxicity, abuse liability, or other biological responses. A further limitation of the present study is that receptor activation was characterized at α4β2, α3β4, and α6/3β2β3 nAChRs, but not at the homomeric α7 subtype. This gap is relevant because α7 nAChRs have been implicated in nicotine-induced convulsive seizures in rodents, although evidence indicates they are not solely responsible, with α5- and β4-containing receptors also contributing to seizure susceptibility [17], [18], [19]. In contrast, nicotine reward is mediated primarily by α4β2 and α6*-containing receptors [20], [21], [22], the principal subtypes evaluated here. Consequently, the differential seizure toxicity observed in unpublished rodent studies cannot be attributed to, or excluded from involving, α7, α4β2, α6β2β3, α5-, or β4-containing receptors based on the present data. Because α7 receptors exhibit distinct gating and rapid desensitization [23], [24], dedicated functional studies (e.g. FLIPR or electrophysiology) are needed to determine whether (S)−6-MN differs from nicotine at this subtype. We have prioritized α7 characterization and electrophysiological confirmation of the α6/3β2β3 partial agonist profile for follow-up studies. Accordingly, the present findings are limited to α4β2, α3β4, and α6/3β2β3 receptors, and the mechanism underlying the differential seizure toxicity of (S)−6-MN remains unresolved. Additional toxicology data are required before a comprehensive safety profile of Nixodine-S can be established. The present results apply only to the tested Nixodine-S formulation and not to 6-MN generally or other nicotine-analog products with different concentrations, solvents, impurities, or co-ingredients. Conclusion In conclusion, Nixodine-S, containing (S)−6-MN, demonstrated lower in vitro cytotoxicity than nicotine, with no evidence of genotoxicity or mutagenicity, while exhibiting receptor-subtype-dependent pharmacological activity comparable to nicotine at the α3β4 and α4β2 receptors, but substantially lower potency at the α6/3β2β3 receptor. These findings provide the first integrated toxicological and pharmacodynamic characterization of Nixodine-S and support its further evaluation as a distinct nicotine analog formulation. Because the study was limited to in vitro assays, additional studies are needed to establish its pharmacokinetic profile, repeated-dose safety, abuse liability, and overall human health risk. Abbreviation List AbbreviationDefinition6-MN6-Methylnicotine(S)−6-MN(S)−6-Methylnicotineµg/mLMicrograms per milliliterAChAcetylcholineATCCAmerican Type Culture CollectionBCSBovine Calf SerumCHOChinese Hamster Ovary cellsCIConfidence intervalCO₂Carbon dioxideDMEMDulbecco’s Modified Eagle MediumDMSODimethyl sulfoxideD-PBSDulbecco’s Phosphate Buffered SalineEC₅₀Half maximal effective concentrationED₅₀Median effective doseEtOHEthanolF−12Nutrient Mixture F−12FBSFetal Bovine SerumFIDFlame Ionization DetectionFLIPRFluorescence Imaging Plate ReaderGCGas ChromatographyHEK293Human Embryonic Kidney 293 cellsIC₅₀Half maximal inhibitory concentrationivMNIn vitro Micronucleus assayLD₅₀Median lethal doseMHb–IPNMedial habenula–interpeduncular nucleusnAChRNicotinic Acetylcholine ReceptorNADPNicotinamide Adenine Dinucleotide PhosphatenHHill coefficientNRUNeutral Red UptakeOECDOrganisation for Economic Co-operation and DevelopmentPDPharmacodynamicPKPharmacokineticrTIReceptor-referenced therapeutic indexS9Rat liver metabolic activation fractionSLSSodium Lauryl SulfateTGTest guideline Funding Statement This study was funded by Ready Mix Naturals, LLC. CRediT authorship contribution statement Willie J. McKinney: Writing – review & editing, Supervision, Methodology, Conceptualization. J. Preston Campbell: Writing – review & editing, Writing – original draft, Visualization, Formal analysis. Roxana E. Weil: Writing – review & editing, Supervision, Methodology, Conceptualization. Rick Avila: Writing – review & editing, Resources, Funding acquisition, Conceptualization. Sandra Costigan: Writing – review & editing, Writing – original draft, Formal analysis. Marissa L. Smith: Writing – review & editing, Writing – original draft, Visualization, Methodology, Formal analysis, Conceptualization. Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Marissa L. Smith reports a relationship with McKinney Regulatory Science Advisors, LLC that includes: consulting or advisory and employment. Sandra Dijkstra-Costigan reports a relationship with McKinney Regulatory Science Advisors, LLC that includes: consulting or advisory. J. Preston Campbell reports a relationship with McKinney Regulatory Science Advisors, LLC that includes: consulting or advisory. Rick Avila reports a relationship with Bonguard Naturals, LLC that includes: board membership, consulting or advisory, employment, and equity or stocks. Roxana E. Weil reports a relationship with McKinney Regulatory Science Advisors, LLC that includes: consulting or advisory. Willie J. McKinney reports a relationship with McKinney Regulatory Science Advisors, LLC that includes: employment and equity or stocks. Rick Avila has patent #11,964,958; 12,358,888; 12,358,889; 12,497,381; 12,478,091 issued to Ready Mix Naturals, LLC. This work was funded by Ready Mix Naturals, LLC. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Handling Editor: Prof. L.H. Lash Data availability Raw data are available upon reasonable request, subject to protection of confidential formulation information. References Associated Data Data Availability Statement Raw data are available upon reasonable request, subject to protection of confidential formulation information.